{"database": "lobbying", "table": "lobbying_activities", "rows": [[1661465, "e1ee4242-67a7-4a55-bb8c-71e41c2cc99d", "Q1", "GSK (FKA GLAXOSMITHKLINE INC.)", 16293, "GSK (FKA GLAXOSMITHKLINE INC.)", 2015, "first_quarter", "CPT", "H.R. 9 - Innovation Act, provisions related to patent litigation reform\nS. 131 - Fair and Immediate Release of Generic Drugs Act, provisions related to patent settlements\nS. 632 - STRONG Patents Act of 2015, provisions relating to post grant proceedings, bad faith demand letters, and PTO diversion\nNo bill # assigned - Biopharmaceutical innovation policy issues\nNo bill # assigned - Biologics data protection issues\nNo bill # assigned - Intellectual property issues, additional data exclusivity request that was part of 21st Century Cures submission", "HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR)", null, 1730000, 0, 0, "2015-04-15T10:45:31.960000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1661465"], "units": {}, "query_ms": 0.5514111835509539, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}